Compile Data Set for Download or QSAR
maximum 50k data
Found 26 Enz. Inhib. hit(s) with all data for entry = 1989
TargetCoagulation factor X(Homo sapiens (Human))
Aventis Pharma Deutschland

LigandPNGBDBM15867(1-{[(5-chloropyridin-2-yl)carbamoyl]methyl}-N-[1-(...)
Affinity DataKi:  1nM ΔG°:  -51.4kJ/molepH: 7.8 T: 2°CAssay Description:The inhibitory effect of test compound for human fXa was determined by using the chromogenic substrates S-2765. The hydrolysis rates of chromogenic s...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCoagulation factor X(Homo sapiens (Human))
Aventis Pharma Deutschland

LigandPNGBDBM15862(1-{[3-(5-chlorothiophen-2-yl)-1,2-oxazol-5-yl]meth...)
Affinity DataKi:  3nM ΔG°:  -48.6kJ/molepH: 7.8 T: 2°CAssay Description:The inhibitory effect of test compound for human fXa was determined by using the chromogenic substrates S-2765. The hydrolysis rates of chromogenic s...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCoagulation factor X(Homo sapiens (Human))
Aventis Pharma Deutschland

LigandPNGBDBM12372(1-{[5-(5-chlorothiophen-2-yl)-1,2-oxazol-3-yl]meth...)
Affinity DataKi:  3nM ΔG°:  -48.6kJ/molepH: 7.8 T: 2°CAssay Description:The inhibitory effect of test compound for human fXa was determined by using the chromogenic substrates S-2765. The hydrolysis rates of chromogenic s...More data for this Ligand-Target Pair
TargetCoagulation factor X(Homo sapiens (Human))
Aventis Pharma Deutschland

LigandPNGBDBM12400(1-[(4-Chloro-phenylcarbamoyl)-methyl]-1H-indole-2-...)
Affinity DataKi:  3nM ΔG°:  -48.6kJ/molepH: 7.8 T: 2°CAssay Description:The inhibitory effect of test compound for human fXa was determined by using the chromogenic substrates S-2765. The hydrolysis rates of chromogenic s...More data for this Ligand-Target Pair
TargetCoagulation factor X(Homo sapiens (Human))
Aventis Pharma Deutschland

LigandPNGBDBM15863(1-{[5-(5-chlorothiophen-2-yl)-1,3,4-thiadiazol-2-y...)
Affinity DataKi:  4nM ΔG°:  -47.9kJ/molepH: 7.8 T: 2°CAssay Description:The inhibitory effect of test compound for human fXa was determined by using the chromogenic substrates S-2765. The hydrolysis rates of chromogenic s...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCoagulation factor X(Homo sapiens (Human))
Aventis Pharma Deutschland

LigandPNGBDBM15865(1-{[(5-chlorothiophen-2-yl)carbamoyl]methyl}-N-[1-...)
Affinity DataKi:  15nM ΔG°:  -44.7kJ/molepH: 7.8 T: 2°CAssay Description:The inhibitory effect of test compound for human fXa was determined by using the chromogenic substrates S-2765. The hydrolysis rates of chromogenic s...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCoagulation factor X(Homo sapiens (Human))
Aventis Pharma Deutschland

LigandPNGBDBM15857(1-[(6-chloro-1-benzothiophen-2-yl)methyl]-N-[1-(pr...)
Affinity DataKi:  40nM ΔG°:  -42.2kJ/molepH: 7.8 T: 2°CAssay Description:The inhibitory effect of test compound for human fXa was determined by using the chromogenic substrates S-2765. The hydrolysis rates of chromogenic s...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCoagulation factor X(Homo sapiens (Human))
Aventis Pharma Deutschland

LigandPNGBDBM15864(1-{[2-(5-chlorothiophen-2-yl)-1,3-thiazol-5-yl]met...)
Affinity DataKi:  57nM ΔG°:  -41.3kJ/molepH: 7.8 T: 2°CAssay Description:The inhibitory effect of test compound for human fXa was determined by using the chromogenic substrates S-2765. The hydrolysis rates of chromogenic s...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCoagulation factor X(Homo sapiens (Human))
Aventis Pharma Deutschland

LigandPNGBDBM15854(1-[2-(4-chlorophenyl)ethyl]-N-[1-(propan-2-yl)pipe...)
Affinity DataKi:  73nM ΔG°:  -40.7kJ/molepH: 7.8 T: 2°CAssay Description:The inhibitory effect of test compound for human fXa was determined by using the chromogenic substrates S-2765. The hydrolysis rates of chromogenic s...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCoagulation factor X(Homo sapiens (Human))
Aventis Pharma Deutschland

LigandPNGBDBM12398(1-(3-Methoxy-benzyl)-1H-indole-2-carboxylic acid (...)
Affinity DataKi:  89nM ΔG°:  -40.2kJ/molepH: 7.8 T: 2°CAssay Description:The inhibitory effect of test compound for human fXa was determined by using the chromogenic substrates S-2765. The hydrolysis rates of chromogenic s...More data for this Ligand-Target Pair
TargetCoagulation factor X(Homo sapiens (Human))
Aventis Pharma Deutschland

LigandPNGBDBM15866(1-{[(3-chlorophenyl)carbamoyl]methyl}-N-[1-(propan...)
Affinity DataKi:  287nM ΔG°:  -37.3kJ/molepH: 7.8 T: 2°CAssay Description:The inhibitory effect of test compound for human fXa was determined by using the chromogenic substrates S-2765. The hydrolysis rates of chromogenic s...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCoagulation factor X(Homo sapiens (Human))
Aventis Pharma Deutschland

LigandPNGBDBM15859(1-{[3-(4-chlorophenyl)-1,2-oxazol-5-yl]methyl}-N-[...)
Affinity DataKi:  400nM ΔG°:  -36.5kJ/molepH: 7.8 T: 2°CAssay Description:The inhibitory effect of test compound for human fXa was determined by using the chromogenic substrates S-2765. The hydrolysis rates of chromogenic s...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCoagulation factor X(Homo sapiens (Human))
Aventis Pharma Deutschland

LigandPNGBDBM15855(1-[2-(2,4-dichlorophenyl)ethyl]-N-[1-(propan-2-yl)...)
Affinity DataKi:  474nM ΔG°:  -36.1kJ/molepH: 7.8 T: 2°CAssay Description:The inhibitory effect of test compound for human fXa was determined by using the chromogenic substrates S-2765. The hydrolysis rates of chromogenic s...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCoagulation factor X(Homo sapiens (Human))
Aventis Pharma Deutschland

LigandPNGBDBM15853(1-[(3-chlorophenyl)methyl]-N-[1-(propan-2-yl)piper...)
Affinity DataKi:  654nM ΔG°:  -35.3kJ/molepH: 7.8 T: 2°CAssay Description:The inhibitory effect of test compound for human fXa was determined by using the chromogenic substrates S-2765. The hydrolysis rates of chromogenic s...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCoagulation factor X(Homo sapiens (Human))
Aventis Pharma Deutschland

LigandPNGBDBM15858(1-{[5-(4-chlorophenyl)-1,2-oxazol-3-yl]methyl}-N-[...)
Affinity DataKi:  810nM ΔG°:  -34.8kJ/molepH: 7.8 T: 2°CAssay Description:The inhibitory effect of test compound for human fXa was determined by using the chromogenic substrates S-2765. The hydrolysis rates of chromogenic s...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCoagulation factor X(Homo sapiens (Human))
Aventis Pharma Deutschland

LigandPNGBDBM15849(1-(4-chlorophenyl)-N-[1-(propan-2-yl)piperidin-4-y...)
Affinity DataKi:  2.10E+3nM ΔG°:  -32.4kJ/molepH: 7.8 T: 2°CAssay Description:The inhibitory effect of test compound for human fXa was determined by using the chromogenic substrates S-2765. The hydrolysis rates of chromogenic s...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCoagulation factor X(Homo sapiens (Human))
Aventis Pharma Deutschland

LigandPNGBDBM15860(1-{[3-(4-chlorophenyl)-1,2,4-oxadiazol-5-yl]methyl...)
Affinity DataKi:  2.23E+3nM ΔG°:  -32.3kJ/molepH: 7.8 T: 2°CAssay Description:The inhibitory effect of test compound for human fXa was determined by using the chromogenic substrates S-2765. The hydrolysis rates of chromogenic s...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCoagulation factor X(Homo sapiens (Human))
Aventis Pharma Deutschland

LigandPNGBDBM15850(1-(3-methoxyphenyl)-N-[1-(propan-2-yl)piperidin-4-...)
Affinity DataKi:  2.48E+3nM ΔG°:  -32.0kJ/molepH: 7.8 T: 2°CAssay Description:The inhibitory effect of test compound for human fXa was determined by using the chromogenic substrates S-2765. The hydrolysis rates of chromogenic s...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCoagulation factor X(Homo sapiens (Human))
Aventis Pharma Deutschland

LigandPNGBDBM15852(1-[(4-chlorophenyl)methyl]-N-[1-(propan-2-yl)piper...)
Affinity DataKi:  2.50E+3nM ΔG°:  -32.0kJ/molepH: 7.8 T: 2°CAssay Description:The inhibitory effect of test compound for human fXa was determined by using the chromogenic substrates S-2765. The hydrolysis rates of chromogenic s...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCoagulation factor X(Homo sapiens (Human))
Aventis Pharma Deutschland

LigandPNGBDBM15861(1-{[2-(4-chlorophenyl)-1,3-thiazol-5-yl]methyl}-N-...)
Affinity DataKi:  2.73E+3nM ΔG°:  -31.8kJ/molepH: 7.8 T: 2°CAssay Description:The inhibitory effect of test compound for human fXa was determined by using the chromogenic substrates S-2765. The hydrolysis rates of chromogenic s...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetProthrombin(Homo sapiens (Human))
Aventis Pharma Deutschland

LigandPNGBDBM12372(1-{[5-(5-chlorothiophen-2-yl)-1,2-oxazol-3-yl]meth...)
Affinity DataKi:  2.76E+3nM ΔG°:  -31.7kJ/molepH: 7.8 T: 2°CAssay Description:The inhibitory effect of test compound for human thrombin was determined by using the chromogenic substrates S-2366. The hydrolysis rates of chromoge...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCoagulation factor X(Homo sapiens (Human))
Aventis Pharma Deutschland

LigandPNGBDBM15851(1-(3-chlorophenyl)-N-[1-(propan-2-yl)piperidin-4-y...)
Affinity DataKi:  9.01E+3nM ΔG°:  -28.8kJ/molepH: 7.8 T: 2°CAssay Description:The inhibitory effect of test compound for human fXa was determined by using the chromogenic substrates S-2765. The hydrolysis rates of chromogenic s...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetProthrombin(Homo sapiens (Human))
Aventis Pharma Deutschland

LigandPNGBDBM15857(1-[(6-chloro-1-benzothiophen-2-yl)methyl]-N-[1-(pr...)
Affinity DataKi:  9.04E+3nM ΔG°:  -28.8kJ/molepH: 7.8 T: 2°CAssay Description:The inhibitory effect of test compound for human thrombin was determined by using the chromogenic substrates S-2366. The hydrolysis rates of chromoge...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCoagulation factor X(Homo sapiens (Human))
Aventis Pharma Deutschland

LigandPNGBDBM15856(1-[2-(3-methoxyphenyl)ethyl]-N-[1-(propan-2-yl)pip...)
Affinity DataKi: >1.00E+4nM ΔG°: >-28.5kJ/molepH: 7.8 T: 2°CAssay Description:The inhibitory effect of test compound for human fXa was determined by using the chromogenic substrates S-2765. The hydrolysis rates of chromogenic s...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetProthrombin(Homo sapiens (Human))
Aventis Pharma Deutschland

LigandPNGBDBM15867(1-{[(5-chloropyridin-2-yl)carbamoyl]methyl}-N-[1-(...)
Affinity DataKi: >1.00E+4nM ΔG°: >-28.5kJ/molepH: 7.8 T: 2°CAssay Description:The inhibitory effect of test compound for human thrombin was determined by using the chromogenic substrates S-2366. The hydrolysis rates of chromoge...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetProthrombin(Homo sapiens (Human))
Aventis Pharma Deutschland

LigandPNGBDBM12400(1-[(4-Chloro-phenylcarbamoyl)-methyl]-1H-indole-2-...)
Affinity DataKi: >1.00E+4nM ΔG°: >-28.5kJ/molepH: 7.8 T: 2°CAssay Description:The inhibitory effect of test compound for human thrombin was determined by using the chromogenic substrates S-2366. The hydrolysis rates of chromoge...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed